Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Ovid Therapeutics Inc.

Market Cap 424M 369M 342M 320M 601M 39.98B 604M 4.06B 1.57B 19.68B 1.59B 1.56B 68.32B P/E 2026 *
-4.7x
P/E 2027 * -4.26x
Enterprise Value 424M 369M 342M 320M 601M 39.98B 604M 4.06B 1.57B 19.68B 1.59B 1.56B 68.32B EV / Sales 2026 *
3,941x
EV / Sales 2027 * 2,542x
Free-Float
93.01%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day-6.20%
1 week-1.30%
Current month-16.85%
1 month-5.02%
3 months-13.36%
6 months+54.42%
Current year+39.26%
1 week 2.22
Extreme 2.22
2.49
1 month 2.16
Extreme 2.162
2.77
Current year 1.36
Extreme 1.36
3.1
1 year 0.29
Extreme 0.2851
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.43
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 31/12/2025
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 27/06/2023
Director TitleAgeSince
Chairman 72 31/03/2014
Director/Board Member 73 29/09/2015
Director/Board Member 81 22/11/2015
Date Insider Type Main position Quantity % Market Cap.
06-14Free

Director

130,000 0.0697%
04-06Free

Director

8,789 0.0067%
04-06Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
-6.20%-1.30%+631.31%-40.96% 424M
+1.44%-1.25%+64.25%+114.23% 55.19B
+4.60%+3.02%+57.38%+48.98% 45.75B
-1.44%+0.39%-14.68%-17.33% 22.98B
-2.69%-2.10%-6.70%+374.02% 20.76B
+3.22%-0.84%+27.88%-20.46% 16.26B
+0.58%+1.08%+18.85%-37.32% 15.42B
-1.01%-2.30%+28.59%+174.08% 13.05B
+4.95%+11.70%+125.78%+252.19% 12.45B
+3.07%+0.14%+29.05% - 12.37B
Average +0.65%+2.28%+96.17%+94.16% 21.47B
Weighted average by Cap. +1.61%+1.48%+41.95%+100.84%

Financials

2026 *2027 *
Net sales 108K 93.73K 86.81K 81.26K 152K 10.14M 153K 1.03M 399K 4.99M 404K 395K 17.34M 167K 145K 135K 126K 236K 15.73M 238K 1.6M 619K 7.74M 626K 612K 26.88M
Net income -77.12M -67.24M -62.28M -58.3M -109M -7.28B -110M -739M -286M -3.58B -289M -283M -12.44B -89.84M -78.33M -72.55M -67.91M -127M -8.48B -128M -861M -334M -4.17B -337M -330M -14.49B
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
18/06/26 2.270 $ -6.20% 15,348,112
17/06/26 2.420 $ +2.54% 3,863,516
16/06/26 2.360 $ +4.42% 2,363,566
15/06/26 2.260 $ -1.74% 1,843,325
12/06/26 2.300 $ +4.07% 2,061,967
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.270USD
Average target price
5.471USD
Spread / Average Target
+141.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!